Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU\u00ae Sprinkle (Deferasirox Granules)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Announces FDA Approval Of A Generic Version Of Perforomist\u00ae (formoterol fumarate) Inhalation Solution","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Announced FDA Approval of A Generic Version of Trileptal\u00ae(oxcarbazepine) Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Pharmaceuticals, Inc. (\"Aucta Pharmaceuticals\") Launches MOTPOLY XR\u2122 (lacosamide) Extended-Release Capsules C-V, the First, and Only Once-Daily Formulation of Lacosamide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Aucta Pharmaceuticals

    Menu

    Aucta Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aucta Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual BoothAucta is a global brand that creates better products from proven molecules.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") Launches MOTPOLY XR™ (lacosamide) Extended-Release Capsules C-V, the First, and Only Once-Daily Formulation of Lacos...

              Details:

              Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for the treatment of partial-onset seizures in adults and in pediatric patients.

              Lead Product(s): Lacosamide

              Therapeutic Area: Neurology Product Name: Motpoly

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 26, 2024

              Aucta Company Banner

              CPhI Worldwide, Milan

              Attending

              envelop Contact Supplier

              Aucta Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual BoothAucta is a global brand that creates better products from proven molecules.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension

              Details:

              Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat partial seizures.

              Lead Product(s): Oxcarbazepine

              Therapeutic Area: Neurology Product Name: Trileptal-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 05, 2022

              Aucta Company Banner

              CPhI Worldwide, Milan

              Attending

              envelop Contact Supplier

              Aucta Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual BoothAucta is a global brand that creates better products from proven molecules.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aucta Announces FDA Approval Of A Generic Version Of Perforomist® (formoterol fumarate) Inhalation Solution

              Details:

              Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).

              Lead Product(s): Formoterol Fumarate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Formoterol Fumarate-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2022

              Aucta Company Banner

              CPhI Worldwide, Milan

              Attending

              envelop Contact Supplier

              Aucta Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual BoothAucta is a global brand that creates better products from proven molecules.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle (Deferasirox Granules)

              Details:

              JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

              Lead Product(s): Deferasirox

              Therapeutic Area: Hematology Product Name: Jadenu

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oakrum Pharma, LLC

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2021

              Aucta Company Banner

              CPhI Worldwide, Milan

              Attending

              envelop Contact Supplier

              Aucta Read More
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY